| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2000-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6fece317fa53ef3bbfa3975f55b4a80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f2357f68a8c3f4b13b1e18d8f030ee1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8272b7f9ee62bb9633214a46f8a231b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_546516be4349b26d7da69fa53a6e893a |
| publicationDate |
2002-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6410514-B1 |
| titleOfInvention |
Tissue specific prodrug |
| abstract |
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-gamma-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9950029-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004038871-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006286574-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8772226-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9138418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1961424-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916161-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011245147-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7282476-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7455840-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7745395-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009136518-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010234300-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005056754-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8669231-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004235095-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006111302-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7838266-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010120697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007081516-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003220241-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007081516-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008089869-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004001801-A1 |
| priorityDate |
1997-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |